FOLFIRI-cetuximab: A multicenter phase II proof-of-concept study of a tailored triple combination therapy for safe dose intensification.
Michele Boisdron-Celle
No relevant relationships to disclose
Olivier Capitain
No relevant relationships to disclose
Jean-Philippe Metges
No relevant relationships to disclose
Antoine Adenis
No relevant relationships to disclose
Jean-Luc Raoul
No relevant relationships to disclose
Thierry Lecomte
No relevant relationships to disclose
You Heng Lam
No relevant relationships to disclose
Roger Faroux
No relevant relationships to disclose
Claude Masliah
No relevant relationships to disclose
Anne-Lise Septans
No relevant relationships to disclose
Virginie Berger
No relevant relationships to disclose
Alain Morel
No relevant relationships to disclose
Erick Gamelin
No relevant relationships to disclose